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2Abstract
Background: Leigh syndrome is a phenotypically and genetically heterogeneous mitochondrial
disorder. While some genetic defects are associated with well-described phenotypes, phenotype-
genotype correlations in Leigh syndrome are not fully explored.
Objective: We aimed to identify phenotype-genotype correlations in Leigh syndrome in a large
cohort of systematically evaluated patients.
Methods: We studied 96 patients with genetically confirmed Leigh syndrome diagnosed and
followed in 8 European centers specializing in mitochondrial diseases.
Results: We found that ataxia, ophthalmoplegia and cardiomyopathy were more prevalent
among patients with mitochondrial DNA defects. Patients with mutations in MT-ND and NDUF
genes with complex I deficiency shared common phenotypic features, such as early development
of central nervous system disease, followed by high occurrence of cardiac and ocular
manifestations. The cerebral cortex was affected in patients with NDUF mutations significantly
more often than the rest of the cohort. Patients with the m.8993T>G mutation in MT-ATP6 gene
had more severe clinical and radiological manifestations and poorer disease outcome compared
to patients with the m.8993T>C mutation.
Conclusion: Our study provides new insights into phenotype-genotype correlations in Leigh
syndrome and particularly in patients with complex I deficiency and with defects in the
mitochondrial ATP synthase.
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3INTRODUCTION
Leigh syndrome is an early-onset progressive neurodegenerative disorder, associated with
defects of mitochondrial oxidative phosphorylation. It is the most common, distinct phenotype
among oxidative phosphorylation disorders in children with an estimated pre-school incidence in
western Sweden of 1 per 34,000 births.[1] The disease is typically characterized by subacute
onset of psychomotor regression and encephalopathy associated with the development of
bilateral symmetrical lesions in the striatum and brainstem, which are the hallmark of the
disease.[2] Leigh disease is genetically highly heterogeneous as evidenced by the more than 75
genes, encoded either by the mitochondrial or the nuclear genome, that are implicated in this
disorder, with more than one-third of these genes identified in the past 5 years.[3]
Some genotypes causing Leigh syndrome are associated with clear and well-described
phenotypic traits, such as cytochrome oxidase deficiency with SURF1 mutations,[6],
methylmalonic aciduria with mutations in SUCLA2,[7,8] and biotin-thiamine-responsive basal
ganglia disease caused by mutations in the SLC19A3 gene.[9,10] Other genetic defects show
weaker correlation with clinical phenotype, particularly as the same mutant protein may result in
highly variable clinical presentations and disease outcomes.[11] For example, the m.8993T>C
mitochondrial DNA mutation has been associated with a less severe phenotype characterized by
later onset and slower disease progression than the m.8993T>G mutation.[4,12] However, the
impact of each of these mutations on survival outcomes and MRI phenotypes has not been
investigated.
Mitochondrial respiratory chain disorders and Leigh syndrome in particular, are multisystem
disorders. Cardiac involvement is common and occurs in 17-40% of patients with mitochondrial
disease.[13,14] Neonatal or infantile hypertrophic cardiomyopathy has been associated with
mutations in NDUFS2,[15] NDUFV2,[16] NDUFA11,[17] NDUFS4,[18] NDUFA2,[19] and
ACAD9,[20], and can occur as an isolated finding in nuclear encoded complex I deficiency or in
combination with encephalopathy, myopathy and/or lactic acidosis. Biochemical investigations
show that complex I deficiency is common in Leigh syndrome, with isolated complex I
deficiency found in as many as 37% in some studies.[2,21,22] Associations between complex I
deficiency in Leigh syndrome and disease-specific clinical and radiological outcomes have,
4however, not been  studied in large cohorts and nor has the incidence of cardiomyopathy or its’
impact on survival.
In a previous study on the natural history of Leigh syndrome, we included 130 patients, of whom
77 had genetic diagnosis at the time of publication.[21] Since then, more of these patients have
been clarified genetically allowing us to study associations between the genotypes and associated
clinical outcomes. The aims of this study were (a) to identify phenotypic features that may
differentiate between mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) associated Leigh
syndrome and (b) to study distinct phenotypes and overlapping phenotypic features across the
different genetic subgroups. In order to address these research questions, we studied patients’
clinical characteristics, biochemical findings, neuroimaging data and disease outcomes across the
different genetic subgroups. Our findings suggest a strong association between certain genetic
defects and the phenotype and disease outcome of Leigh syndrome.
METHODS
Study design and population
The present study is part of a large cohort study performed within the Mitochondrial Clinical and
Research Network (MCRN). The study was conducted at 8 European centers in Gothenburg,
Rotterdam, Helsinki, Copenhagen, Stockholm, Brussels, Bergen and Oulu. These are national
expert/reference centers specializing in mitochondrial diseases. We included patients with Leigh
syndrome who were diagnosed and followed at the participating centers and fulfilled the
inclusion criteria: (i) clinical features compatible with Leigh syndrome, e.g. psychomotor
regression, dystonia, ataxia and/or brainstem dysfunction and (ii) MRI or CT or
neuropathological findings of Leigh syndrome, as follows: bilateral symmetrical lesions in the
basal ganglia, and/or thalamus, and/or brainstem. Patients were excluded from the study if they
had known mitochondrial phenotypes other than Leigh syndrome. Patient data were collected
with the help of electronic data capture. The methodology along with longitudinal natural history
data on the overall study population of 130 patients are described elsewhere.[21]
5We used whole exome sequencing either alone or after targeted sequencing or gene-panel
sequencing failed to identify the cause. While ours was not a population-based study, the results
reflect the genetic diversity found in these areas of Europe.
Muscle pathology suggestive of mitochondrial myopathy was considered with any one of the
following findings: mitochondrial proliferation or structurally abnormal mitochondrial on light
and/or electron microscopy, ragged red fibers, abnormal oxidative staining (i.e. cytochrome
oxidase -COX; succinate dehydrogenase -SDH; nicotinamide adenine dinucleotide reductase -
NADH; Mg-ATPase). The following muscle findings were considered non-specific: fiber
atrophy (type I or II or combined), infiltration of macrophages or T-cells and lipid accumulation.
Statistical considerations
The statistical evaluations performed were mainly exploratory. Survival outcomes were
estimated with the help of Kaplan-Meier analysis. Chi-square test was used to test the association
between categorical variables. All statistical tests were two-sided and performed at a 0.05
significance level.
Ethical considerations
The study was approved by the local ethical committee of each participating center, as per the
standing regulatory requirements.
RESULTS
Here we present the results from 96 patients with genetically verified Leigh syndrome. The
geographic distribution and genetic variability of our patients is depicted in Figure 1. 65 patients
had Leigh syndrome caused by mutations in nuclear genes, while 31 patients had mtDNA
associated disease. Most patients were of Caucasian origin (68/96).
nDNA associated Leigh syndrome
We studied 65 patients (43 males; 22 females) with Leigh syndrome due to nDNA mutations.
The median age of onset was 5 months (range: intrauterine – 10.6 years). Hypotonia was the
most common feature of nDNA associated Leigh syndrome (55/65), followed by dyskinesia
(40/65) and hypertonia and/or spasticity (34/65). Ataxia was less common (16/65). Ocular
involvement was seen in more than half of these patients (35/65), including nystagmus (15),
6optic atrophy (13), strabismus (11), visual impairment (9), ophthalmoplegia (7), retinopathy (5),
saccadic eye movement (2), abnormal pupillary reflex (2) and diplopia (1). Eleven patients
developed heart disease, as follows: cardiomyopathy (5), arrhythmias (3), heart valve disease (2)
and conduction defect (1). Sensorineural hearing loss was common (18/65), mainly in patients
with defects in SUCLA2, SUCLG1 and SERAC1.
Eight distinct genetic subgroups were identified, as shown in Table 1. Six patients did not fit into
any of these subgroups. They had the following genetic defects: BCS1L (1/6); c12orf65 (1/6);
ECHS1 (1/6); ETHE1 (1/6); PNPT1 (1/6) and TSFM (1/6).
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8Mitochondrial changes on muscle biopsy were found in the majority of patients with SURF1
defects (5/7), including COX deficiency (4/7) and mitochondrial proliferation (2/7). Among the
other genetic subgroups, mitochondrial abnormalities in muscle were less common (12 patients,
Table 1). The group overall muscle pathology findings included COX deficiency (5), SDH
deficiency (4), abnormal NADH staining (2), mitochondrial proliferation (1) and structurally
abnormal mitochondria on electron microscopy (1).
Mutations in the nuclear-encoded subunits of the NADH:ubiquinone oxidoreductase causing
complex I deficiency (NDUF group) were associated with the following distinct phenotypes:
NDUF associated phenotypes (n=12)
The genotypic spectrum involved mutations in the following genes: NDUFS4 (2/12), NDUFS7
(2/12), NDUFV2 (2/12), NDUFAF2 (2/12), NDUFAF5 (2/12), NDUFA9 (1/12) and NDUFA12
(1/12). Four patients were of Caucasian origin, while the remainder were from North Africa and
the Middle East. The most common presenting signs were hypotonia (8) and nystagmus (4). Two
patients had hypertrophic cardiomyopathy at disease onset, with mutations in NDUFV2 (1) and
NDUFS4 (1) genes.
The disease course was characterized by hypotonia (11), hypertonia or spasticity (8) and dystonia
(7). In addition to nystagmus (6), patients developed strabismus (3), optic atrophy (3), visual
impairment (3), ophthalmoplegia (1), retinopathy (1) and abnormal saccadic eye movement (1).
Intellectual disability was found in all tested patients (7/7) and was severe or profound in 5 of
them. Six patients suffered from respiratory complications, mainly central hypoventilation. Six
patients developed heart disease, as follows: hypertrophic and/or dilated cardiomyopathy (3/5),
mitral valve insufficiency (1/5), pulmonary stenosis (1/5) and conduction defect (1/5). Four
patients presented renal abnormalities, including kidney dysplasia (renomegaly (1) and renal
aplasia (1)), abnormal renal vein anatomy (1) and renal tubular acidosis (1). These were the only
patients in our cohort with renal involvement, underlying that patients with mutations in NDUF
genes had significantly higher risk of developing kidney disease or dysplasia (p<0.0005).
All patients in the NDUF group had complex I deficiency (12/12), 3 in combination with
complex II or complex III deficiencies. Two patients had abnormal muscle pathology findings
9suggestive of mitochondrial myopathy, one with enzyme histochemical SDH deficiency and
another with combined SDH and COX deficiencies.
Neuroimaging of the brain revealed involvement of the deep grey matter in all patients, with
lesions extending to more than one of the deep grey matter structures (9/12) [Table 1].
Infratentorial involvement was less common (3/12). The cerebral cortex was affected in 7
patients as follows: frontal, temporal or generalized cortical atrophy (4), T2 signal hyperintensity
(2), stroke-like lesions involving the frontal lobe unilaterally (1), and increased lactate signal in
the entire cerebrum on spectroscopy (1). The cortical involvement found in the NDUF group was
significantly more prevalent compared to the other genetic subgroups (p=0.0005).
Six patients, with a median age of 18.5 years, were still living while the remaining 6 patients
died at a median age of 10.5 months. The latter had mutations in NDUFAF2 (2/6), NDUFA9
(1/6), NDUFS4 (1/6), NDUFS7 (1/6) and NDUFV2 (1/6). They developed multi-system disease
with generalized or partial epileptic seizures (5/6), central hypoventilation (5/6), heart disease
(4/6) and renal involvement (3/6). Increased lactate levels of 4-15 mmol/l were found in the
blood (5/5) and the cerebrospinal fluid (CSF) (2/2).
mtDNA associated Leigh syndrome
The genotypic and phenotypic features of these 31 patients (18 males; 13 females) grouped into
three distinct subgroups, are outlined in Table 1. The median age of onset was 11 months (range:
intrauterine - 19 years). In addition to hypotonia, the most common neurologic features were
ataxia (17/31) and dyskinesia (16/31). Hypertonia and/or spasticity were less common (11/31).
Ophthalmoplegia was found in 8 patients (25.8%) and 6 patients developed heart disease,
cardiomyopathy (5/6) and conduction defect (1/6), respectively. Three patients developed
sensorineural hearing loss. Central hypo- and/or hyperventilation was seen in 15 patients, of
whom 12 had brainstem lesions on neuroimaging. The brainstem was the second most affected
part of the brain (17/30) after the basal ganglia (25/30).
Muscle pathology suggestive of mitochondrial myopathy was found in 9 patients and included
the following findings:  COX deficiency (3), abnormal SDH staining (2), abnormal NADH
staining (2), low Mg-ATPase staining (1), mitochondrial proliferation/ragged red fibers (4),
structurally abnormal mitochondrial on electron microscopy (2).
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Two distinct phenotypes caused by two different missense mutations at position m.8993 in the
MT-ATP6 gene are described in more detail below.
Mutation m.8993T>G
All 7 patients showed a severe phenotype with onset by 6 months of age. The mutation was
homoplasmic or > 90% heteroplasmic in all patients. Five of 7 patients died by the age of 3 years
[Figure 2]. The disease onset was characterized by hypotonia (6/7), muscle weakness (4/7) and
failure to thrive (4/7). The patients developed dyskinesia (5/7), central hypoventilation (4/7),
nystagmus (3/7) and epilepsy (3/7). Macular atrophy was seen in one patient. All patients had
increased lactate levels in blood and CSF. Combined NADH and SDH deficiencies were found
on muscle enzyme histochemistry in one patient, while another patient had non-specific findings
of infiltration of macrophages and muscle fiber atrophy. Respiratory chain complex deficiencies
were found in 4 patients, 2 of them had isolated complex V deficiency and 2 had generally low
complex activities. Brain MRI (6/7) showed T2 signal hyperintensity and/or atrophy of the basal
ganglia (5/6), midbrain (3/6), cerebellum (3/6), supratentorial white matter (2/6) and cerebral
cortex (1/6).
Mutation m.8993T>C
As opposed to the severe phenotype of m.8993T>G, all 4 patients with T>C mutations had an
attenuated phenotype. The mutation was homoplasmic or > 90% heteroplasmic in all patients.
All patients developed symptoms by the age of 1.5 years and all were alive at a median follow-
up of 6.1 years [Figure 2]. The clinical phenotype was characterized by ataxia (4/4), delayed
speech development and dysarthria (4/4), diminished deep tendon reflexes (2/4) and retinopathy
(2/4). Lactate levels were normal in blood (4/4) and slightly increased in CSF (2/4). Muscle fiber
degeneration was found on biopsy in one patient. Two patients had normal respiratory chain
enzyme activities, one had isolated complex V deficiency and another had generally low
complex activities. Brain neuroimaging revealed signal changes and/or atrophy restricted to the
basal ganglia [Figure 2].
Phenotypic differences and overlaps between mtDNA and nDNA associated Leigh
syndrome
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No significant differences were seen in terms of age of onset or disease outcome between these
two major groups. Patients with mtDNA mutations were more likely to develop ataxia
(p=0.004), while patients with nDNA mutations were more likely to develop sensorineural
hearing loss (p=0.046). Ophthalmoplegia and cardiomyopathy were more common in the
mtDNA compared to the nDNA group without reaching statistical significance (p=0.058 and
p=0.200 respectively).
Patients with complex I deficiency due to mutations in either structural or assembly proteins
(MT-ND and NDUF subgroups) represented 25% of our cohort. These patients had significantly
higher occurrence of cardiac involvement (p=0.001) and ocular findings (p=0.023) compared to
the rest of the cohort.
Distinct phenotypic features and phenotypic overlaps across the 7 most common genetic
subgroups, i.e. SERAC1, MT-ATP6, MT-ND, NDUF, SURF1, SLC19A3 and SUCLA2, are
summarized in Figure 3. Survival outcomes of these genetic subgroups (number of patients,
median, min, max) are shown in Figure 4. In addition to the m.8993T>G associated outcomes
described above, poor survival outcomes were found in patients with (a) SLC19A3 mutations
who did not receive treatment with thiamine and/or biotin: 8 of 12 patients died at a median age
of 1 month, (b) SURF1 mutations: 5 of 8 patients died at a median of 2 years and (c) SERAC1
mutations: 4 of 5 patients died at a median age of 10.5 years.
DISCUSSION
Our study included 96 patients with genetically confirmed Leigh syndrome diagnosed and
followed in 8 centers in Northern and Western Europe. This is, to our knowledge, the largest
phenotype-genotype correlation study in Leigh syndrome to be performed on systematically
evaluated patients. We identified distinctive as well as overlapping phenotypic features across
the genetic subgroups.
We analyzed the different phenotypes caused by missense mutations in the MT-ATP6,
m.8993T>C and m.8993T>G, and found the following novel correlations: patients with the
m.8993T>G mutation had early onset, before 6 months, and poor disease outcome with death by
3 years of age. They also more frequently had epilepsy, failure to thrive, dyskinesia and
brainstem dysfunction.  Patients with m.8993T>C mutation had later debut, longer survival and
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less severe neurological outcome. Patients with the m.8993T>C mutation showed isolated striatal
lesions radiologically, as opposed to lesions in multiple brain areas both supra- and
infratentorially found in patients with the m.8993T>G mutation.
The percentage of patients with mutations in MT-ND genes was higher in our study compared to
previous studies.[14,23] We found that patients with mutations in MT-ND and NDUF genes with
complex I deficiency shared clinical features, that differed from the rest of the cohort, such as
significantly higher occurrence of cardiac and ocular involvement. These patients also showed
similar radiological involvement of multiple deep grey matter structures, often with sparing of
the cerebellum. These findings underline the importance of identifying the biochemical defect in
oxidative phosphorylation disorders, as similar metabolic phenotypes often lead to similar
clinical and radiological phenotypes despite very different genetic mechanisms.
Leigh syndrome is considered to be the most common phenotype among children with
mitochondrial disease due to complex I deficiency.[24-26] Other phenotypes include
leukoencephalopathy,[27] neonatal cardiomyopathy and encephalopathy,[28,29] and fatal
infantile lactic acidosis.[17,25] Our patients with complex I defect presented with a relatively
homogeneous phenotype characterized by the early onset of multi-organ disease as has been
described in previous studies.[26,30] This was typically characterized by central nervous system,
respiratory, ocular, cardiac, auditory and occasionally renal involvement. Furthermore, we found
patients with Leigh syndrome due to mutations in NDUF genes to have significantly higher risk
of developing kidney disease or dysplasia.
Cardiomyopathy, hypertrophic or dilated, was found in 10% of our patient cohort and was twice
as prevalent in patients with mtDNA mutations compared to the nDNA group. However, in all
patients with mtDNA mutations, cardiomyopathy was not present at disease onset but developed
later. Two of our patients presented with infantile hypertrophic cardiomyopathy at disease onset.
These patients had mutations in NDUFS4 and NDUFA2 confirming previous reports.[18,19]
Heart disease alone was not related to poorer survival, neither in the NDUF group, nor in the
entire study population, in contrast to previous studies that have correlated heart disease with
poorer survival in patients with mitochondrial diseases.[13]
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Our patients with nuclear encoded complex I deficiency had the characteristic symmetrical deep
gray matter lesions, but also showed lesions in the cerebral cortex significantly more often than
the rest of the cohort. These lesions included cortical atrophy, T2-signal hyperintensities or
stroke-like lesions. Radiological involvement of the cortex, commonly reflected by global
atrophy, was found in 12% of patients with Leigh syndrome regardless of genetic cause in one
study.[31] Neuropathology studies in Leigh syndrome suggest that the characteristic striatal and
brainstem lesions are due to primary energy deprivation.[23] The pathological process causing
cortical lesions appears to differ and has been considered as a neurodegenerative process causing
neuronal loss and atrophy.[23] The cortical lesions pertaining to either signal changes or stroke-
like lesions seen in our patients cannot entirely be attributed to secondary neurodegeneration, but
suggest a different or complementary pathogenic mechanism. Supratentorial stroke-like lesions
in combination with brainstem lesions are commonly seen in mtDNA encoded complex I
deficiency.[32] Increased complex I gene expression in the cortex has been seen during cerebral
development. This is related to intense neurogenesis, neuronal differentiation and migration.[33]
Our findings could thus support the hypothesis that proposes an important role for complex I
activity in the neurogenesis and neuroplasticity of specific areas in the human brain;
compromised complex I gene expression may therefore lead to primary cortical
degeneration.[34]
The prognosis of Leigh syndrome due to nuclear encoded complex I deficiency is poor,
especially in patients with core subunit mutations. Thus far no clear association between the
prognosis and the underlying genetic, neuroimaging, or biochemical defects exists.[24,26] Our
studied patients had variable lifespan from early death to survival beyond the fifth decade. Early
onset is associated with poorer survival, but this is true for Leigh syndrome regardless of the
genetic cause.[21,25] In addition, patients in our study who died at preschool age shared the
clinical features of early onset multi-system disease with epileptic seizures, central
hypoventilation, cardiac and renal involvement.
Muscle histopathology is an important diagnostic tool in suspected mitochondrial disease, along
with respiratory chain enzyme activities. Specific myopathic findings are linked to specific
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mitochondrial myopathies and to certain mtDNA defects in particular.[35] In our study, the only
genetic subgroup with consistently abnormal histopathologic findings on muscle biopsy was the
SURF1 subgroup showing COX deficiency and mitochondrial proliferation as described in the
literature.[36] In the total cohort, only 32% of patients with either mtDNA or nDNA associated
Leigh syndrome had histopathological findings in muscle suggestive of mitochondrial disease.
Furthermore, 27% of our cohort had normal respiratory chain enzyme activities, and 15% had
normal lactate levels in both blood and CSF. Patients with mutations in the NDUF genes showed
combined complex deficiencies. This has been previously shown with mutations in complex I
subunit genes (either mtDNA or nDNA) and attributed to disruption of the respiratory chain
supercomplexes by the truncated complex.[37,38]
Our study describes the largest cohort of Leigh disease to date and adds considerably to existing
knowledge concerning phenotype-genotype associations. We provide new insights into the
phenotypic panorama of certain genotypes considered to be common causes of Leigh syndrome,
e.g. mutations in the MT-ATP6 and NDUF genes. Further, we have identified important
phenotypic differences between mtDNA- and nDNA-associated Leigh syndrome and showed
that diagnosis usually requires the combination of different investigations, such as laboratory and
genetic testing, in addition to thorough clinical and radiological evaluation. The discovery of
new genetic causes makes phenotype-genotype correlations difficult and the diagnosis of Leigh
disease challenging. Studies such as ours are important therefore to improve recognition of this
disease, understanding its outcome and to ensure that potential treatments can be properly
evaluated.
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FIGURE LEGENDS
Figure 1. Patients’ geographic distribution and genetic variability (n=96)
Figure 2. Survival analysis and brain MRI of patients with the m.8993T>C versus the
m.8993T>G associated Leigh syndrome
Figure 3. Distinct phenotypic features and overlaps in the 7 most common genetic subgroups:
SERAC1, MT-ATP6, MT-ND, NDUF, SURF1, SLC19A3, SUCLA2
Figure 4. Age (median, min, max) at last follow-up or death for the 7 most common genetic
subgroups: SERAC1, MT-ATP6, MT-ND, NDUF, SURF1, SLC19A3, SUCLA2




